Business Model

ViThera’s innovative EnLact™ technology delivers drugs directly to diseased epithelial sites (intestinal wall, vaginal wall, skin) so the drugs are available in high local concentrations. ViThera’s probiotic bacteria are evolved to associate closely with epithelial cells. ViThera enhances these probiotics to produce and release drugs right against their target tissue where they are needed.

We have excellent in vitro and in vivo proof-of-concept data. Our accelerated development plan allows us to treat patients significantly earlier than typical drug development plans.

Because VT301 is naturally safe and works to heal the intestines, not only to stop flare-ups, this treatment will benefit patients with all stages of Crohn’s Disease and Ulcerative Colitis and will be used to keep patients in remission.

Investment Opportunities
Investment Opportunities exist to help ViThera advance the development of our internal lead product VT301. We are currently raising funds to allow for the development of VT301 through phase I clinical testing. Contact contact@vitherapharma.com for information on investment opportunities.